This study is being conducted to compare the effectiveness and safety of datopotamab deruxtecan against docetaxel in patients with a specific type of Non-Small Cell Lung Cancer. The cancer being studied is non-squamous non-small cell lung cancer, which is a type of lung cancer that does not grow in the flat, scale-like cells found on the surface of the lungs. The study focuses on patients whose cancer is TROP2-positive, meaning the cancer cells have a specific protein called TROP2 on their surface, and who do not have actionable genomic alterations, which are specific genetic changes in the cancer cells that can be targeted by other existing drugs.

The cancer being investigated is also classified as advanced or metastatic, meaning it has grown beyond the original part of the lung or has spread to other parts of the body. Participants in this trial will receive their treatment through intravenous use, which involves delivering the medication directly into a vein using a liquid solution for infusion. The study will monitor how long the cancer remains stable without growing and the overall length of time patients live during the trial.